

Pier Francesco Ferrucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600850/publications.pdf>

Version: 2024-02-01

77
papers

5,189
citations

201674

27
h-index

91884

69
g-index

79
all docs

79
docs citations

79
times ranked

6399
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
2	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
3	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600E Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
4	Novel Biomarkers and Druggable Targets in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 81.	3.7	5
5	Meta-analysis of randomized phase II-III trials evaluating triplet combinations of immunotherapy and targeted therapy for BRAF V600-mutant unresectable or metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9541-9541.	1.6	3
6	Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. <i>European Journal of Cancer</i> , 2022, 172, 332-339.	2.8	6
7	A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. <i>Cells</i> , 2021, 10, 70.	4.1	8
8	Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. <i>Cancers</i> , 2021, 13, 1383.	3.7	120
9	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
10	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
11	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.0	44
12	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
13	Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial. <i>Nutrients</i> , 2021, 13, 1931.	4.1	20
14	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745.	7.0	35
15	Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. <i>Current Oncology Reports</i> , 2021, 23, 138.	4.0	11
16	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	0
17	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	2.8	10
18	ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma. <i>Cancers</i> , 2020, 12, 3366.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma. <i>Anti-Cancer Drugs</i> , 2020, 31, 652-654.	1.4	3
20	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	3.2	8
21	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e001806.		110
22	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	30.7	256
23	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 772-781.	6.3	144
24	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
25	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
26	Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. <i>European Radiology</i> , 2019, 29, 1882-1892.	4.5	31
27	Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. <i>Acta Oncologica</i> , 2018, 57, 1131-1133.	1.8	7
28	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	10.7	1,089
29	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22
30	Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. <i>European Radiology</i> , 2017, 27, 4372-4378.	4.5	30
31	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3.	7.2	1
32	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	2.8	76
33	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2.	1.2	41
34	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. <i>Oncotarget</i> , 2017, 8, 79809-79815.	1.8	27
35	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
36	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	1.6	244

#	ARTICLE	IF	CITATIONS
37	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). Cancer Research, 2017, 77, CT075-CT075.	0.9	34
38	Prognostic significance of hematological profiles in melanoma patients. International Journal of Cancer, 2016, 139, 1618-1625.	5.1	40
39	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology, 2016, 34, 9505-9505.	1.6	50
40	Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).. Journal of Clinical Oncology, 2016, 34, TPS9596-TPS9596.	1.6	4
41	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology, 2015, 33, LBA1-LBA1.	1.6	9
42	A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.. Journal of Clinical Oncology, 2015, 33, TPS9090-TPS9090.	1.6	5
43	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology, 2015, 33, LBA1-LBA1.	1.6	28
44	Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.. Journal of Clinical Oncology, 2015, 33, e20060-e20060.	1.6	0
45	Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients.. Journal of Clinical Oncology, 2015, 33, 9034-9034.	1.6	0
46	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy, 2014, 14, 955-967.	3.1	20
47	Maspin expression and melanoma progression: a matter of sub-cellular localization. Modern Pathology, 2014, 27, 412-419.	5.5	16
48	Electrochemotherapy: A treatment with specific intent in specific skin tumorsâ€”Experience from the European Institute of Oncology, Milan.. Journal of Clinical Oncology, 2014, 32, e20042-e20042.	1.6	0
49	Brain metastasis in melanoma patients: Associations with BRAF status and age.. Journal of Clinical Oncology, 2014, 32, e20037-e20037.	1.6	0
50	Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy. PLoS ONE, 2013, 8, e78820.	2.5	13
51	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).. Journal of Clinical Oncology, 2013, 31, 9035-9035.	1.6	5
52	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9070-9070.	1.6	9
53	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients (pts) with metastatic melanoma: Analysis of peripheral neuropathy.. Journal of Clinical Oncology, 2013, 31, e20025-e20025.	1.6	1
54	Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment. Current Topics in Medicinal Chemistry, 2012, 12, 11-31.	2.1	8

#	ARTICLE	IF	CITATIONS
55	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	10.7	273
56	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	4.2	118
57	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8513-8513.	1.6	5
58	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8529-8529.	1.6	7
59	Surgery in stage IV melanoma patients: Results from a single institution.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19035-e19035.	1.6	3
60	Vulvar melanoma: A monocentric retrospective study on 29 cases.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19036-e19036.	1.6	0
61	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1395-1407.	3.1	8
62	Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. <i>Dermatologic Therapy</i> , 2010, 23, 651-661.	1.7	123
63	HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. <i>Expert Review of Vaccines</i> , 2009, 8, 1513-1526.	4.4	16
64	Oncophage [®] (vitespen [®]) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?. <i>Hum Vaccin</i> , 2009, 5, 727-737.	2.4	13
65	Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 925-931.	1.3	27
66	Efficacy of 90Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3063-3063.	1.4	1
67	High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1871-1879.	5.0	49
68	Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. <i>British Journal of Haematology</i> , 2007, 136, 521-538.	2.5	131
69	High activity ⁹⁰ Y-ibritumomab tiuxetan (Zevalin [®]) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007, 139, 590-599.	2.5	45
70	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. <i>Blood</i> , 2007, 110, 1890-1890.	1.4	3
71	Efficacy of ⁹⁰ Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. <i>Blood</i> , 2007, 110, 4499-4499.	1.4	4
72	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. <i>Blood</i> , 2006, 108, 2720-2720.	1.4	11

#	ARTICLE	IF	CITATIONS
73	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6039-6046.	7.0	18
74	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	2.5	151
75	Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. <i>Oncogene</i> , 1998, 16, 2905-2913.	5.9	69
76	In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 241-250.	2.8	27
77	The acute promyelocytic leukemia-specific PML-RAR α fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. <i>Cell</i> , 1993, 74, 423-431.	28.9	583